1,721,018 research outputs found
sj-pptx-1-jet-10.1177_15266028211057085 – Supplemental material for A Systematic Review and Meta-Analysis of 12-Month Patency After Intervention for Iliofemoral Obstruction Using Dedicated or Non-Dedicated Venous Stents
No full textSupplemental material, sj-pptx-1-jet-10.1177_15266028211057085 for A Systematic Review and Meta-Analysis of 12-Month Patency After Intervention for Iliofemoral Obstruction Using Dedicated or Non-Dedicated Venous Stents by Ghulam M. Majeed, Krishan Lodhia, Jemima Carter, Jack Kingdon, Rachael I. Morris, Adam Gwozdz, Athanasios Saratzis and Prakash Saha in Journal of Endovascular Therapy</p
sj-docx-1-jet-10.1177_15266028231173297 – Supplemental material for Acute Kidney Injury Following Revascularization in Patients With Chronic Limb-Threatening Ischemia and Non-Dialysis-Dependent Chronic Kidney Disease: Insights From the NSQIP Database at 30-Day Follow-Up
No full textSupplemental material, sj-docx-1-jet-10.1177_15266028231173297 for Acute Kidney Injury Following Revascularization in Patients With Chronic Limb-Threatening Ischemia and Non-Dialysis-Dependent Chronic Kidney Disease: Insights From the NSQIP Database at 30-Day Follow-Up by Konstantinos Stavroulakis, Nikolaos Tsilimparis, Athanasios Saratzis, Barbara Rantner, Jan Stana, Anand Dayama, Mark G. Davies and Ryan Gouveia e Melo in Journal of Endovascular Therapy</p
sj-pdf-1-vmj-10.1177_1358863X241231943 – Supplemental material for Safety and effectiveness of the phoenix atherectomy device for endovascular treatment of common femoral and popliteal arteries: Results of the EN-MOBILE trial
No full textSupplemental material, sj-pdf-1-vmj-10.1177_1358863X241231943 for Safety and effectiveness of the phoenix atherectomy device for endovascular treatment of common femoral and popliteal arteries: Results of the EN-MOBILE trial by Christoph Schöfthaler, Nicola Troisi, Giovanni Torsello, Amila Jehn, Michael Lichtenberg, Jan C Karcher, Konstantinos Stavroulakis, Mario D’Oria, Athanasios Saratzis, Hany Zayed, Martin Andrassy and Grigorios Korosoglou in Vascular Medicine</p
A New Concept to Help Deal With Dissections in Peripheral Angioplasty
No full textPeripheral Arterial Disease (PAD) affects nearly a fifth of those over the age of 60 in the Western World</div
A New Concept to Help Deal With Dissections in Peripheral Angioplasty
No full textPeripheral Arterial Disease (PAD) affects nearly a fifth of those over the age of 60 in the Western World</div
Ilio-ureteric Fistula: A Rare Cause of Haematuria
No full textIlio-ureteric Fistula: A Rare Cause of Haematuri
Ilio-ureteric Fistula: A Rare Cause of Haematuria
No full textIlio-ureteric Fistula: A Rare Cause of Haematuri
Endovascular abdominal aortic aneurysm repair in the geriatric population.
No full textAbdominal aortic aneurysm (AAA) is a relatively common pathology among the elderly. More people above the age of 80 will have to undergo treatment of an AAA in the future. This review aims to summarize the literature focusing on endovascular repair of AAA in the geriatric population. A systematic review of the literature was performed, including results from endovascular abdominal aortic aneurysm repair (EVAR) registries and studies comparing open repair and EVAR in those above the age of 80. A total of 15 studies were identified. EVAR in this population is efficient with a success rate exceeding 90% in all cases, and safe, with early mortality and morbidity being superior among patients undergoing EVAR against open repair. Late survival can be as high as 95% after 5 years. Aneurysm-related death over long-term follow-up was low after EVAR, ranging from 0 to 3.4%. Endovascular repair can be offered safely in the geriatric population and seems to compare favourably with open repair in all studies in the literature to date
Cardiovascular risk in patients with small abdominal aortic aneurysms
No full textBackground: Abdominal aortic aneurysm (AAA) is a cardiovascular health problem. Ultrasound screening has been shown to reduce the risk of AAA-related, but not all-cause, mortality. The recent introduction of screening in several countries has meant that thousands of patients with a small AAA (<5·5cm) that does not require immediate treatment are diagnosed annually. We sought to investigate the cardiovascular profiles of patients with ectatic aortas and assess whether participation in screening reduces cardiovascular risk.
Methods: We used three sets of data: from the National Health Service AAA Screening Programme (NAAASP) during the 2013–14 round that were linked with Health Episode Statistics (HES) (235 409 individuals); a subset of the Framingham Study population who had an abdominal CT scan in 2004–05 and were followed up for 10 years (1383 individuals); and data for patients with a small AAA who had been in surveillance for at least 1 year in the UK Aneurysm Growth Study (UKAGS) (384 individuals) or from a national UK audit (1538 individuals), to assess cardiovascular risk and events.
Findings: In the linked NAAASP–HES cohort, cardiovascular mortality was 0·30% (95% CI 0·28–0·32) for individuals with an abdominal aortic diameter of less than 2·5 cm; 0·81% (0·51–1·11) for those between 2·5 and 2·9 cm; and 1·30% (0·90–1·71) for those less than 3·0 cm. Death from a cardiovascular event was more likely for individuals with a small AAA than for those without AAA (risk ratio 4·33, 95% CI 3·15–5·97). In the Framingham cohort, abdominal aortic diameter was independently associated with cardiovascular events (hazard ratio [HR] 1·1, 95% CI 1·02–1·18; p<0·0001). An abdominal aortic diameter of more than 2·5 cm was also associated with cardiovascular events (HR 7·6, 95% CI 5·1–11·3; p<0·0001). In the UKAGS and audit populations, patients were not more likely to take antiplatelet agents or statins after entering screening surveillance; cholesterol concentrations and blood pressure also increased.
Interpretation: In these contemporary large cohorts of patients with small AAA, cardiovascular events and death were common and were the leading cause of death. The implication is that patients are not more likely to receive cardiovascular protection if they enter screening or surveillance with existing protocols. Cardiovascular risk reduction interventions should be implemented in screening programmes in the future
- …
